Capabilities by Region: United Kingdom
Greenhill has considerable advisory experience in the United Kingdom. Our Managing Directors and professionals have advised clients on transactions involving many of the leading companies in the region and have access to a vast network of corporate relationships throughout the United Kingdom.
Greenhill established its presence in the United Kingdom in January 1998 with the opening of a London office.
For more information on Greenhill’s advisory practice in the United Kingdom and our capabilities in the region, please contact President David Wyles or Head of U.K. M&A Dean Rodrigues in our London Office.
Below we highlight a few of the transactions on which we have advised in this region:
Recent Transactions
Sort By

LCH.Clearnet SA

Advised LCH.Clearnet Group Limited, a leading multi-asset class European clearing house, on a sale of LCH.Clearnet SA, its French-regulated operating subsidiary, to Euronext N.V. that was ultimately terminated

Subsidiaries and affiliates of Empresas Indumotora S.A.

Advised Inchcape PLC, a global leader in automotive retail and distribution, on the acquisition of a multi-country scale distribution business in Chile, Peru, Colombia, and Argentina for $290m (approximately £234m)

Host Europe Group

Advised GoDaddy, the largest domain name registrar worldwide and a leading web hosting provider, on its acquisition of Host Europe Group, the largest privately owned web services provider in Europe

Peacock Foods

Advised Greencore Group plc, a leading international manufacturer of convenience foods based in Ireland, on the proposed acquisition of Peacock Foods, a manufacturing partner for consumer packaged goods companies in the US.

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)